तुलना करने के लिए मीट्रिक्स | NANEXA | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधNANEXAपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −47.6x | −8.3x | −0.4x | |
PEG अनुपात | −1.39 | 0.14 | 0.00 | |
क़ीमत/बुक | 8.8x | 1.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 34.5x | 1.6x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 72.2% | 49.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | −11.1% | 6.5% | अनलॉक करें |
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a drug from lenalidomide for the treatment of multiple myeloma. The company has collaborations with Novo Nordisk to evaluate PharmaShell technology; and Moderna for the development of pharmaceutical products with active substances. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.